Recent Updates
Recently added Catalysts
PMI Neutral Sentiment Score: 60/100

Picard Issues Statement on Intraday Stock Price

Key Takeaway: Picard Medical, Inc. addressed recent stock price volatility, stating it is not aware of any undisclosed changes in its operations or financial condition. The company emphasized its commitment to its strategic goals while ensuring compliance with securities laws. Additionally, Picard's SynCardia Systems retains its position as the leader in total artificial heart technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Picard Medical reaffirms stability with no undisclosed changes in operations.
  • The company continues to focus on strategic operational priorities.
  • Picard Medical's SynCardia remains a leader in total artificial heart technology.

Full Press Release Details

Picard Issues Statement on Intraday Stock Price
Tucson, AZ - October 24, 2025 - Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company's operations or financial condition, that would account for the recent volatility in its stock price.
The Company remains focused on executing its strategic and operational priorities and will continue to comply with all disclosure obligations under applicable securities laws.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Forward-Looking Statements
This release may contain forward-looking statements within the meaning of federal securities laws. Such statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update or revise any forward-looking statements.
LifeSci Advisors LLC
Picard Medical, Inc./SynCardia Systems, LLC

Frequently Asked Questions

What caused the volatility in Picard Medical's stock price?

Picard Medical has stated it is unaware of any undisclosed changes causing stock volatility.

What product is SynCardia known for?

SynCardia is known for the world's first commercially-approved total artificial heart.

Where can I find more information about Picard Medical?

More information is available on Picard Medical's website and SEC filings.

How many total artificial hearts has SynCardia implanted?

SynCardia has performed over 2,100 total artificial heart implants globally.

Last updated: Oct 27, 2025